Latest Concord Drugs stock price

Concord Drugs P/E Ratio

CONCORD • P/E ratio trend, valuation band, and sector comparison — all formatted to support journal-based trading review.
Current P/E Ratio
227.88
High Valuation
Very High - High growth expectations or significantly overvalued

Current Valuation Metrics

P/E Ratio 227.88
Current Price ₹77.48
EPS (TTM) ₹0.34
Exchange BSE

Valuation Signal

Signal Overvalued
Historical Avg 33.56
Historical Range 33.56 - 33.56
Percentile 100.0%

Sector Context

Sector Average 49.36
Sector Median 25.87
Sector Rank #11 of 140
Sector Percentile 7.9%

Earnings Breakdown (TTM)

TTM EPS ₹0.39
Sept 2025 ₹0.19
Mar 2025 ₹0.04

Key P/E Ratio Insights for Concord Drugs

  • Stock appears overvalued with PE of 227.88, suggesting caution for new investments
  • Current PE is 579.0% above historical average
  • Trading at premium to sector average PE of 49.36

View the CONCORD equity price for detailed stock performance.

P/E Ratio Historical Trend for Concord Drugs

Historical P/E ratio trend based on annual earnings data. Lower P/E ratios may indicate undervaluation, while higher ratios suggest growth expectations.

Historical P/E Ratio Data

Year P/E Ratio EPS (₹) Year-end Price (₹) Exchange Valuation
2022 33.56 0.97 ₹32.55 BSE High

Sector P/E Ratio Comparison

Comparing Concord Drugs with other companies in Healthcare sector
Sector Average
49.36
Sector Median
25.87
Lowest P/E
0.97
Highest P/E
993.26
Companies
140
Company Symbol P/E Ratio Market Cap (₹ Cr) Valuation
Welcure Drugs & Pharmace… WELCURE 0.97 ₹36 Low
Murae Organisor MURAE 3.0 ₹43 Low
Ind Swift Laboratories INDSWFTLAB 4.67 ₹1,166 Low
Amwill Health Care AMWILL 6.5 ₹67 Low
Medicamen Organics MEDIORG 6.94 ₹27 Low
Galaxy Medicare GML 7.25 ₹24 Low
Unichem Laboratories UNICHEMLAB 7.74 ₹2,188 Low
Zenith Drugs ZENITHDRUG 7.9 ₹76 Low
Brooks Laboratories BROOKS 8.01 ₹184 Low
Vasundhara Rasayans VRL 9.97 ₹37 Low